Intracellular Activation of Anticancer Therapeutics Using Polymeric Bioorthogonal Nanocatalysts. Issue 5 (13th December 2020)

• Record Type: Journal Article
• Authors: Zhang, Xianzhi; Landis, Ryan F.; Keshri, Puspam; Cao‐Milán, Roberto; Luther, David C.; Gopalakrishnan, Sanjana; Liu, Yuanchang; Huang, Rui; Li, Gengtan; Malassiné, Morgane; Uddin, Imad; Rondon, Brayan; Rotello, Vincent M.
• Other Names: Hou Yanglong guestEditor.; Bu Wenbo guestEditor.; Ai Hua guestEditor.; Lu Zheng‐Rong guestEditor.; Lammers Twan guestEditor.
• Is Part Of: Advanced healthcare materials. Volume 10:Issue 5(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-12-13
• Subjects: anticancer therapeutics -- bioorthogonal chemistry -- nanozymes -- polymers; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1002/adhm.202001627
• Languages: English
• ISSNs: 2192-2640

Abstract

Abstract: Bioorthogonal catalysis provides a promising strategy for imaging and therapeutic applications, providing controlled in situ activation of pro‐dyes and prodrugs. In this work, the use of a polymeric scaffold to encapsulate transition metal catalysts (TMCs), generating bioorthogonal "polyzymes, " is presented. These polyzymes enhance the stability of TMCs, protecting the catalytic centers from deactivation in biological media. The therapeutic potential of these polyzymes is demonstrated by the transformation of a nontoxic prodrug to an anticancer drug (mitoxantrone), leading to the cancer cell death in vitro. Abstract : Ruthenium catalysts are encapsulated into the hydrophobic pocket of polymers to provide bioorthogonal "polyzymes" with enhanced catalyst stability. These polyzymes uncage imaging and anticancer therapeutics in cells.